Published in Vaccine Weekly, August 17th, 2005
The trial is a multi-center, double-blind, randomized, placebo-controlled, study of orally administered SP01A as monotherapy treatment of HIV-infected patients.
This trial is designed to accrue treatment-experienced HIV patients that are failing on their current anti-viral therapy. Patients are entered into a 4-week wash-out phase followed by 10 days of monotherapy treatment with SP01A. The primary analysis for the study...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.